Zhao S, Zhu Y, Schultz RD, et al
Current clinical evidence from a meta-analysis of phase 2 and three studies of tirzepatide in participants with T2D indicates that tirzepatide treatment is not associated with an increased risk of MACE-4, a composite outcome comprising the four outcomes cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, and hospitalization due to unstable angina (HR = 0.80
This luxurious body wash is designed to transform your daily shower routine into a soothing and nourishing experience
For tirzepatide, additional contraceptive precautions are specifically recommended after initiation and dose increases, while routine additional precautions are not generally required for semaglutide or liraglutide based on current evidence
Diabetologia 60(8):13851389
Zhang T, Perkins MH, Chang H, Han W, de Araujo IE